Hiroi Tomioka Selected Research

Cholinergic Antagonists (Anticholinergics)

1/2016	Mini Review: Anticholinergic Activity as a Behavioral Pathology of Lewy Body Disease and Proposal of the Concept of "Anticholinergic Spectrum Disorders".
11/2015	Assessment of Cognitive Dysfunction Caused by Anticholinergic Burden in Japanese Alzheimer's Disease Patients, Using the Most Commonly Used Scales in Japan.
1/2015	Pharmacotherapy for Neurocognitive Disorders Based on the Hypothesis of Endogenous Appearance of Anticholinergic Activity.
1/2015	Hypothesis of Endogenous Anticholinergic Activity in Alzheimer's Disease.
1/2015	Beyond the Hypothesis of Serum Anticholinergic Activity in Alzheimer's Disease: Acetylcholine Neuronal Activity Modulates Brain-Derived Neurotrophic Factor Production and Inflammation in the Brain.
1/2015	A Review of the Role of Anticholinergic Activity in Lewy Body Disease and Delirium.
1/2015	Anticholinergic Activity and Alzheimer's Disease.
1/2015	Serum Anticholinergic Activity as an Index of Anticholinergic Activity Load in Alzheimer's Disease.
1/2015	Anticholinergic Activity and Schizophrenia.
1/2015	Demonstrating the Role of Anticholinergic Activity in a Mood Disorder.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroi Tomioka Research Topics

Disease

15	Alzheimer Disease (Alzheimer's Disease) 01/2016 - 02/2009
7	Inflammation (Inflammations) 09/2021 - 01/2015
4	Delirium 09/2021 - 01/2015
4	Cognitive Dysfunction 11/2015 - 01/2015
3	Lewy Body Disease (Lewy Body Dementia) 01/2016 - 01/2014
2	Neurocognitive Disorders (Clerambault Syndrome) 11/2015 - 01/2015
1	Sleep Initiation and Maintenance Disorders (Insomnia) 09/2022
1	Sleep Wake Disorders 09/2022
1	Communicable Diseases (Infectious Diseases) 09/2021
1	Confusion (Bewilderment) 11/2015
1	Diabetes Mellitus 01/2015
1	Factitious Disorders (Ganser Syndrome) 01/2015
1	Schizophrenia (Dementia Praecox) 01/2015
1	Bipolar Disorder (Manic Depressive Psychosis) 01/2015
1	Disease Progression 01/2015
1	Mood Disorders (Mood Disorder) 01/2015
1	Amnesia (Dissociative Amnesia) 01/2013
1	Glaucoma 01/2013
1	Parkinson Disease (Parkinson's Disease) 09/2012
1	Panic Disorder (Panic Attack) 01/2008
1	Major Depressive Disorder (Major Depressive Disorders) 01/2008

Drug/Important Bio-Agent (IBA)

14	Cholinergic Antagonists (Anticholinergics)IBA 01/2016 - 09/2012
7	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2016 - 01/2013
5	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2015 - 01/2013
4	Donepezil (Aricept)FDA LinkGeneric 01/2015 - 08/2010
2	suvorexantIBA 09/2022 - 09/2021
2	Pharmaceutical PreparationsIBA 09/2022 - 09/2021
2	CytokinesIBA 01/2016 - 01/2015
1	lemborexantIBA 09/2022
1	Antipsychotic Agents (Antipsychotics)IBA 09/2021
1	Therapeutic UsesIBA 09/2021
1	Hypnotics and Sedatives (Sedatives)IBA 09/2021
1	LipidsIBA 01/2015
1	Oxygen (Dioxygen)IBA 01/2015
1	Cholinesterases (Cholinesterase)IBA 01/2015
1	Choline O-Acetyltransferase (Choline Acetyltransferase)IBA 01/2015
1	Amyloidogenic ProteinsIBA 01/2015
1	Duloxetine Hydrochloride (Cymbalta)FDA Link 01/2015
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2015
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2015
1	AntibodiesIBA 01/2015
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2015
1	Cholinergic Agents (Cholinergics)IBA 01/2014
1	Insulin-Like Growth Factor I (IGF-1)IBA 08/2010
1	Biomarkers (Surrogate Marker)IBA 08/2010
1	Oxyhemoglobins (Oxyhemoglobin)IBA 02/2009
1	Hemoglobins (Hemoglobin)IBA 01/2008

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2015 - 01/2015
1	Therapeutics 01/2015
1	Aftercare (After-Treatment) 01/2013